

MATERIAL SAFETY DATA SHEET

1. Product and Company Identification

Product Name

MUCINEX® FAST-MAX™ Adult Caplets - Cold & Sinus

CAS#

This MSDS is designed for workplace employees, emergency personnel and for other conditions and situations where there is a greater potential for large-scale or prolonged exposure, in accordance with requirements of the U.S. Government's Occupational

Safety and Health Administration (OSHA).

This MSDS is not applicable for consumer use of our products. For consumer use, all precautionary and first aid language is provided on the product label in accordance with

the applicable government regulation.

Product Use

Pain Reliever/Fever Reducer, Expectorant, Nasal Decongestant

Distributed by

Reckitt Benckiser Morris Corporate Center IV 399 Interpace Parkway

P.O. Box 225

Mixture

Parsippany, NJ 07054-0225

In Case of Emergency: 1-800-338-6167 Transportation Emergencies: 24 Hour Number: North America: CHEMTREC: 1-800-424-9300 Outside North America: 1-703-527-3887

LEGEND
HMIS/NFPA

Severe 4
Serious 3
Moderate 2
Slight 1
Minimal 0





2. Hazards Identification

Emergency overview

This product is regulated by the US FDA as an over-the-counter, monograph drug.

Liver warning: This product contains acetaminophen. Severe liver damage may occur if you take:

* more than 12 caplets in 24 hours, which is the maximum daily amount.

*with other drugs containing acetaminophen.

*3 or more alcoholic drinks daily while using this product.

Do not use with any other drug containing acetaminophen (prescription or nonprescription). If you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist.

Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking the product. Ask a doctor before use if you have:

*Liver disease, heart disease, diabetes, high blood pressure, thyroid disease, trouble urinating due to an enlarged prostate gland, persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis or emphysema, cough that occurs with too much phlegm (mucus).

Ask a doctor or pharmacist before use if you are taking the blood thinning drug warfarin. When using this product do not use more than directed.

Stop use and ask a doctor if:

*Nervousness, dizziness or sleeplessness occur.

*Pain, nasal congestion or cough gets worse or lasts more than 7 days.

*Fever gets worse or lasts more than 3 days.

*Redness or swelling is present.

*New symptoms occur.

*Cough comes back, or occurs with rash or persistent headache. These could be signs of a serious condition.

If pregnant or breast feeding, ask a health professional before use. KEEP OUT OF REACH OF CHILDREN.

Overdose warning: Taking more than the recommended dose (overdose) may cause liver damage. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222). Quick medical attention is critical for adults as well as for children even if you do not notice any signs of symptoms.

Potential short term health effects

Routes of exposure Eye, Skin contact, Inhalation, Ingestion.

Eyes No risks anticipated in normal use. Exposure to dusts from broken tablets may cause

irritation.

Skin No risks anticipated in normal use. Prolonged skin exposure to dusts from broken tablets

may cause irritation.

Inhalation No risks anticipated in normal use. Exposure to dusts from broken tablets may cause

respiratory tract irritation.

Ingestion No risks anticipated in normal use. Avoid occupational ingestion.

Target organs Eyes. Respiratory system. Skin.

Chronic effectsThe finished product is not expected to have chronic health effects.

Signs and symptoms May cause irritation.

OSHA Regulatory Status This product is a "Hazardous Chemical" as defined by the OSHA Hazard Communication

Standard, 29 CFR 1910.1200.

Potential environmental effects See section 12.

3. Composition / Information on Ingredients

Ingredient(s)	CAS#	Percent
Acetaminophen	103-90-2	20 - 40
Cellulose	9004-34-6	20 - 40
Guaifenesin	93-14-1	20 - 40
Phenylephrine hydrochloride	61-76-7	0.1 - 1
Titanium oxide	13463-67-7	0.1 - 1

#22944 Page 2 of 8 Issue date 12-Sep-2012

4. First Aid Measures

First aid procedures

Eye contact In case of contact with eyes, rinse immediately with plenty of water and seek medical

advice.

Skin contact In the event of occupational skin contact, wash contaminated area thoroughly.

Inhalation Move person to non-contaminated air. Call a physician if symptoms develop or persist.

Ingestion In the event of occupational ingestion, seek medical advice. Induction of vomiting is not a

recommended first-aid procedure.

Notes to physician Treat patient symptomatically.

General advice If you feel unwell, seek medical advice (show the label where possible). Ensure that

medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Show this safety data sheet to the doctor in attendance. Avoid contact with

eyes and skin. Keep out of reach of children.

5. Fire Fighting Measures

Flammable properties Not flammable by OSHA criteria.

Dusts may form an explosive mixture with air.

Extinguishing media

Suitable extinguishing media Treat for surrounding material.

Unsuitable extinguishing media Not available

Protection of firefighters

Specific hazards arising from

the chemical

Not available

Protective equipment for

firefighters

Firefighters should wear full protective clothing including self contained breathing

apparatus.

Hazardous combustion products

Explosion data

May include and are not limited to: Oxides of carbon. Oxides of nitrogen.

Sensitivity to mechanical impact Not available
Sensitivity to static discharge Not available

6. Accidental Release Measures

Personal precautions Keep unnecessary personnel away. Do not touch or walk through spilled material. Do not

touch damaged containers or spilled material unless wearing appropriate protective

clothing. Keep people away from and upwind of spill/leak.

Environmental precautions Do not discharge into lakes, streams, ponds or public waters.

Inform the relevant authorities if the product has caused environmental pollution.

Methods for containment

Methods for cleaning up

Prevent entry into waterways, sewers, basements or confined areas.

Before attempting clean up, refer to hazard data given above. Use broom or dry vacuum to collect material for proper disposal without raising dust. Rinse area with water.

Prevent large spills from entering sewers or waterways. Contact emergency services

and supplier for advice.

7. Handling and Storage

Handling Tamper evident: do not use if outer package is opened or blister is torn or broken.

Use good industrial hygiene practices in handling this material.

Avoid contact with skin and clothing.

Avoid contact with eyes.
Keep container tightly closed.
Use only with adequate ventilation.
Wash thoroughly after handling.
Avoid breaking or crushing tablets.

Storage Store at 15-30°C (59-86°F).

Store in a closed container away from incompatible materials.

Protect from direct sunlight. Keep out of reach of children.

Evnocura limita	
Exposure limits Ingredient(s)	Exposure Limits
Acetaminophen	ACGIH-TLV
	Not established
	OSHA-PEL
	Not established
Cellulose	ACGIH-TLV
	TWA: 10 mg/m3
	OSHA-PEL OSHA-PEL
	TWA: 15 mg/m3
Guaifenesin	ACGIH-TLV
	Not established
	OSHA-PEL
	Not established
Phenylephrine hydrochloride	ACGIH-TLV
	Not established
	OSHA-PEL
	Not established
Titanium oxide	ACGIH-TLV
	TWA: 10 mg/m3
	OSHA-PEL
	TWA: 15 mg/m3
Engineering controls	General ventilation normally adequate.
Personal protective equipment	
	Consult the product label for special protection or precautions that have been identif for using this product under directed consumer use conditions. The following recommendations are given for workplace employees, emergency personnel and for other conditions and situations where there is a greater potential for large-scale or prolonged exposure.
Eye / face protection	No special requirements under normal use conditions. Emergency
	responders should wear full eye and face protection.
Hand protection	No special requirements under normal use conditions. Emergency responders should wear impermeable gloves.
Skin and body protection	As required by employer code.
Respiratory protection	No special requirements under normal use conditions. Emergency responders should wear self-contained breathing apparatus (SCBA) to avoid inhalation of vapours generated by this product during a spill or other clean-up operations.
General hygiene considerations	Handle in accordance with good industrial hygiene and safety practice.

9. Physical and Chemical Properties

Appearance Tablet.

Color Orange
Form Tablets

Odor None

Odor threshold Not available

Physical state Solid

pH Not available

Freezing point

Boiling point

Not available

Not available

Pour pointNot availableEvaporation rateNot availableFlash pointNot availableAuto-ignition temperatureNot availableFlammability limits in air, lower, %Not applicable

by volume

Flammability limits in air, upper, %

by volume

Not applicable

Vapor pressureNot availableVapor densityNot availableSpecific gravityNot availableOctanol/water coefficientNot available

10. Stability and Reactivity

Reactivity Accumulation of dust, static discharge, sparks, high temperatures.

Possibility of hazardous reactions Hazardous polymerization does not occur.

Chemical stability Stable under recommended storage conditions.

Conditions to avoidDo not mix with other chemicals. This product may react with oxidizing agents.

Incompatible materials Caustics.

Hazardous decomposition products May include and are not limited to: Oxides of carbon. Oxides of nitrogen.

11. Toxicological Information

Component analysis - LC50		
Ingredient(s)	LC50	
Acetaminophen	Not available	
Cellulose	Not available	
Guaifenesin	Not available	
Phenylephrine hydrochloride	Not available	
Titanium oxide	Not available	
Component analysis - Oral LD50		
Ingredient(s)	LD50	
Acetaminophen	2404 mg/kg rat; 338 mg/kg mouse	
Cellulose	5000 mg/kg rat	
Guaifenesin	1510 mg/kg rat; 690 mg/kg mouse	
Phenylephrine hydrochloride	350 mg/kg rat; 120 mg/kg mouse	
Titanium oxide	24000 mg/kg rat	

Effects of acute exposure

Eye No risks anticipated in normal use. Exposure to dusts from broken tablets may cause

irritation.

SkinNo risks anticipated in normal use. Prolonged skin exposure to dusts from broken tablets

may cause irritation.

Inhalation No risks anticipated in normal use. Exposure to dusts from broken tablets may cause

respiratory tract irritation.

IngestionNo risks anticipated in normal use. Avoid occupational ingestion.SensitizationThe finished product is not expected to have chronic health effects.Chronic effectsThe finished product is not expected to have chronic health effects.

#22944 Page 5 of 8 Issue date 12-Sep-2012

CarcinogenicityThe finished product is not expected to have chronic health effects.MutagenicityThe finished product is not expected to have chronic health effects.Reproductive effectsThe finished product is not expected to have chronic health effects.

TeratogenicityThe finished product is not expected to have chronic health effects.

Name of Toxicologically Synergistic Not available

Products

12. Ecological Information

Ecotoxicity See below

Ecotoxicity - Freshwater Fish - Acute Toxicity Data

Acetaminophen 103-90-2 96 Hr LC50 Pimephales promelas: 814 mg/L [flow-through]

Ecotoxicity - Water Flea - Acute Toxicity Data

Acetaminophen 103-90-2 48 Hr EC50 Daphnia magna: 6.1 - 14 mg/L

Persistence / degradability

Bioaccumulation / accumulation

Mobility in environmental media

Environmental effects

Aquatic toxicity

Partition coefficient

Chemical fate information

Not available

Not available

Not available

13. Disposal Considerations

Disposal instructions Dispose in accordance with all applicable regulations.

Do not flush to surface water or sanitary sewer systems.

Waste from residues / unused

products

Not available

Contaminated packaging Not available

14. Transport Information

UN/ID N.o. Not applicable

U.S. Department of Transportation (DOT): Classification: Not regulated

Proper shipping name

U.S. DOT Hazard Class

Not applicable

Subsidiary Risk

Not applicable

Packing group

Not applicable

DOT RQ (lbs)

ERG NO

Not applicable

Not applicable

Transportation of Dangerous Goods (TDG - Canada): Classification: Not regulated

Proper shipping name Not applicable

Status Not applicable

Packing group Not applicable

IMDG (Marine Transport): Classification: Not regulated

Proper shipping name Not applicable
Class Not applicable
Subsidiary Risk Not applicable
Packing group Not applicable
IMDG Page Not applicable

Marine pollutantNot applicableEMSNot applicableMFAGNot applicableMaximum QuantityNot applicable

IATA/ICAO (Air): Classification: Not regulated

Proper shipping name Not applicable
Class Not applicable
Subsidiary Risk: Not applicable
Packing group Not applicable
Maximum Quantity Not applicable

15. Regulatory Information

Occupational Safety and Health Administration (OSHA)

29 CFR 1910.1200 hazardous

chemical

res

US Federal regulations This product is a "Hazardous Chemical" as defined by the OSHA Hazard Communication

Standard, 29 CFR 1910.1200.

All components of this product are either on the Toxic Substances Control Act list (TSCA)

or exempt.

CERCLA (Superfund) reportable quantity

None

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - Yes

Delayed Hazard - Yes Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

Section 302 extremely N

hazardous substance

Section 311 hazardous chemical Yes

Clean Air Act (CAA) Not available
Clean Water Act (CWA) Not available

State regulations

U.S. - Illinois - Toxic Air Contaminant Carcinogens

Titanium oxide 13463-67-7 IARC 2B Carcinogen

U.S. - Massachusetts - Right To Know List

Cellulose 9004-34-6 Present Titanium oxide 13463-67-7 Present

U.S. - Minnesota - Hazardous Substance List

Cellulose 9004-34-6 Present (dust, paper fiber)

Titanium oxide 13463-67-7 Present (dust)
U.S. - New Jersey - Right to Know Hazardous Substance List
Cellulose 9004-34-6 sn 3227
Titanium oxide 13463-67-7 sn 1861

U.S. - Pennsylvania - RTK (Right to Know) List

Cellulose 9004-34-6 Present Titanium oxide 13463-67-7 Present

U.S. - Rhode Island - Hazardous Substance List

Cellulose 9004-34-6 Toxic Titanium oxide 13463-67-7 Toxic

Inventory status

Country(s) or regionInventory nameOn inventory (yes/no)*United States & Puerto RicoToxic Substances Control Act (TSCA) InventoryNo

A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

16. Other Information

Disclaimer

This product should only be used as directed on the label and for the purpose intended.

To the best of our knowledge the information contained berein is accurate. However,

To the best of our knowledge, the information contained herein is accurate. However, neither the above named supplier nor any of its subsidiaries assumes any liability whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only

hazards that exist.

Further information MUCINEX® FAST-MAX™ Adult Caplets - Cold & Sinus - 6/20 ct. 0390598v2.0

MUCINEX® FAST-MAX™ Adult Caplets - Cold & Sinus - 6/30 ct. 0390598v2.0

Issue date 12-Sep-2012 Effective date 01-Sep-2012

Prepared by Reckitt Benckiser Regulatory Department 800-333-3899

Other information For an updated MSDS, please contact the supplier/manufacturer listed on the first

page of the document.

This MSDS conforms to the ANSI Z400.1/Z129.1-2010 Standard.